Advertisement

Topics

Teva & Xenon Announce Topical TV-45070 Missed Endpoint in Phase 2 Study

13:00 EDT 29 Jun 2017 | Drug Discovery Development

This was a Phase II proof of concept study seeking to understand the potential for a topical route of Nav1.7 blockade in PHN.
Contributed Author: 

Original Article: Teva & Xenon Announce Topical TV-45070 Missed Endpoint in Phase 2 Study

NEXT ARTICLE

More From BioPortfolio on "Teva & Xenon Announce Topical TV-45070 Missed Endpoint in Phase 2 Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...